Amgen CEO talks trial results of cardiac drug Repatha

Key Findings on Cholesterol and Heart Health - There is no level of cholesterol that's considered good, except when managed with specific drugs [1] - Lowering LDL cholesterol to a median of 45 reduces the risk of a first heart attack by 36% [2] - Adding Rapatha to optimized therapy prevents first occurrences of heart attack by 36% and shows a strong signal for preventing cardiac death [2] Clinical Trial Insights - The trial unequivocally answers that lower LDL cholesterol is better, even to a targeted median of 45 [3] - Meaningful benefits were demonstrated over the placebo group, which was controlled on what was previously considered optimal therapy [3] - The trial addresses questions that have been on the minds of investigators, physicians, and patients [3]